Ratings Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
1.92 ^USD	-1.54%		-5.88%	-20.00%

24/04	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
25/03	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The stock, which is currently worth 2024 to 0.23 times its sales, is clearly overvalued in comparison with peers.
The company appears to be poorly valued given its net asset value.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
EMERGENT BIOSOLUTIONS INC.	-20.00%	101M	C
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes